Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Change in Acquisitions & Divestments (2016 - 2025)

Fate Therapeutics (FATE) has disclosed Change in Acquisitions & Divestments for 10 consecutive years, with $66.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Acquisitions & Divestments rose 8.86% year-over-year to $66.3 million, compared with a TTM value of $311.9 million through Dec 2025, down 5.68%, and an annual FY2025 reading of $311.9 million, down 5.68% over the prior year.
  • Change in Acquisitions & Divestments was $66.3 million for Q4 2025 at Fate Therapeutics, down from $81.4 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $263.1 million in Q4 2021 and bottomed at $60.9 million in Q4 2024.
  • Average Change in Acquisitions & Divestments over 5 years is $121.1 million, with a median of $107.7 million recorded in 2021.
  • The sharpest move saw Change in Acquisitions & Divestments soared 1138.09% in 2021, then tumbled 42.78% in 2023.
  • Year by year, Change in Acquisitions & Divestments stood at $263.1 million in 2021, then tumbled by 36.57% to $166.9 million in 2022, then tumbled by 42.78% to $95.5 million in 2023, then plummeted by 36.21% to $60.9 million in 2024, then increased by 8.86% to $66.3 million in 2025.
  • Business Quant data shows Change in Acquisitions & Divestments for FATE at $66.3 million in Q4 2025, $81.4 million in Q3 2025, and $71.6 million in Q2 2025.